Company intelligence / Profile preview
Arbutus Biopharma Corporation
Warminster, Pennsylvania, United Statessec.gov ↗
- Ownership
- Public · ABUS
- Development stage
- Phase 2
01
Overview
Achieved a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon; initiating Phase 2b clinical trial in first half of 2025
- Therapeutic areas
- Infectious Diseases
- Modalities
- RNAi therapeuticsoral capsid inhibitorsoral PD-L1 inhibitorslipid nanoparticle (LNP) delivery technology
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
Request access →03
Partnerships
Genevant SciencesAlnylam PharmaceuticalsAcrotech Biopharma LLCGritstone OncologyX-ChemProteros biostructures
04
Financials
- Market cap
- $1B
- Total revenue
- $1M
- Enterprise value
- $922.4M
Beyond the preview
Go deeper on Arbutus Biopharma Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arbutus Biopharma Corporation.